Accelerating sales of Merck KGaA’s oral multiple sclerosis therapy Mavenclad helped the company to a double-digit rise in healthcare sales in the third quarter, and a rise in its full-year ...
Europe’s CHMP top scientific committee gave a positive opinion for approval to cladribine, with the proposed trade name Mavenclad, for relapsing forms of MS with high disease activity.
US pharma group Merck said the UAE Ministry of Health and Prevention has approved the registration of its Mavenclad (cladribine tablets) for the treatment of adult patients with highly active ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback